Deloitte NextGen Therapies Industry Working Group.
Thomas Heathman and Nick Treuil will join advanced therapy leaders to tackle key challenges in cell and gene therapy.
Deloitte University in Westlake, Texas
Mar 5 - 7, 2025
Thomas Heathman and Nick Treuil will join advanced therapy leaders to tackle key challenges in cell and gene therapy.
Deloitte University in Westlake, Texas
Mar 5 - 7, 2025
Location:
Between March 5 – 7, Ori’s CCO Thomas Heathman and Chief of Staff Nick Treuil will join advanced therapy leaders to address key challenges in cell and gene therapy.
Thomas will also speak on the panel “Navigating the Future: Model Strategies & Innovation”.
Deloitte’s NextGen Therapies Industry Working Group, established in 2019, serves as a forum for exchanging perspectives and driving actionable discussion on critical topics that impact patient access to transformational therapies. The IWG hosts executive meetings to discuss relevant industry topics, address pain points, and identify opportunities to raise the tide for all the boats.
Oribiotech Ltd 2025 © All rights reserved.
Oribiotech Ltd is registered in England and Wales. "Ori”, “Ori Biotech”, "Iro" and the O icon are registered trademarks of Oribiotech Ltd.
Company registration 09757696.